17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
84
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms

Conditions

Vasomotor Symptoms

Trial Timeline

Feb 1, 2006 โ†’ Dec 1, 2009

About 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)

17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial) is a approved stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00472004. Target conditions include Vasomotor Symptoms.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00472004ApprovedCompleted

Competing Products

20 competing products in Vasomotor Symptoms

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
77
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
52
esomeprazole + placeboAstraZenecaPre-clinical
23
MK-6913 + 17-ฮฒ estradiol + Placebo to MK-6913 + Placebo to 17-ฮฒ estradiol + MK-6913 25 mgMerckPhase 2
52
Erenumab + PlaceboAmgenPhase 1
32
DVS-233 SRPfizerPhase 3
76
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
76
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
32
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
76
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
76
Treatment A + Treatment B + Treatment CBayerPhase 1
30
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
30
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
74
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
30
Elinzanetant (BAY3427080)BayerPhase 1
30
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
30
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
30
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
74
BAY3427080BayerPhase 1
30
Elinzanetant (BAY3427080) + RosuvastatinBayerPhase 1
30